Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

24
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
24
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Chemical Synapses01:26

Chemical Synapses

9.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.1K
Chemical Synapses01:26

Chemical Synapses

10.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.8K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

4.8K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
4.8K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

INFECTIVE CORONARY THROMBOSIS: CASE REPORT WITH UNUSUAL FEATURES.

Canadian Medical Association journal·2010
Same author

Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients.

Gut·2006
Same author

Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection.

Journal of viral hepatitis·2001
Same author

Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells.

Journal of neuroimmunology·1995
Same author

Detection of alpha-subunit isoforms in human muscle acetylcholine receptor by specific T cells from a myasthenia gravis patient.

Proceedings. Biological sciences·1993
Same author

Cellular and humoral immunity in patients with insulin-dependent diabetes.

Lancet (London, England)·1993

Related Experiment Video

Updated: Apr 22, 2026

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
05:44

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

Published on: December 9, 2022

3.8K

Mapping the autoimmunizing epitopes on acetylcholine receptors.

G Harcourt1, A Jermy

  • 1Department of Neurological Science, Royal Free Hospital School of Medicine, London NW3 2PF, UK.

Immunology Today
|October 8, 2014
PubMed
Summary

Myasthenia gravis (MG) causes muscle weakness due to loss of acetylcholine receptors (AChR). Autoantibodies and complement may cause this loss, with DNA technology offering new insights into MG's immune mechanisms.

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers
13:10

In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers

Published on: August 1, 2014

10.8K

Related Experiment Videos

Last Updated: Apr 22, 2026

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
05:44

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

Published on: December 9, 2022

3.8K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers
13:10

In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers

Published on: August 1, 2014

10.8K

Area of Science:

  • Immunology
  • Neuroscience
  • Molecular Biology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness and fatigability.
  • This occurs due to the loss of functional acetylcholine receptors (AChR) at the neuromuscular junction.
  • Pathological mechanisms include anti-AChR autoantibody modulation and complement-mediated lysis of the postsynaptic membrane.

Purpose of the Study:

  • To explore the immunological mechanisms underlying myasthenia gravis.
  • To highlight the utility of DNA technology in studying MG.
  • To understand the structural and functional aspects of acetylcholine receptors in the context of MG.

Main Methods:

  • Review of existing research on AChR structure and function.
  • Discussion of immunological investigations into MG.
  • Application of DNA technology products for studying MG.

Main Results:

  • The structure of AChR is crucial for its function as a neurotransmitter receptor.
  • Anti-AChR autoantibodies and complement activation are key factors in AChR loss in MG.
  • DNA technology provides powerful tools for dissecting the immunological basis of MG.

Conclusions:

  • Understanding AChR structure is vital for comprehending MG pathogenesis.
  • Investigating the interplay between autoantibodies, complement, and AChR is essential for MG research.
  • The integration of DNA technology offers promising avenues for advancing MG immunology and potential therapeutic strategies.